ADPKD Guide
Readable, evidence-first ADPKD treatment, symptoms, diet, trials, and research updates for patients, families, and clinicians.
Methodology References Support GitHub
Patient Guide Treatment Trials Cure
More
Newly Diagnosed Tolvaptan Diet Symptoms Clinicians Methodology References Support
ADPKD Clinician Guide

ADPKD Evidence Summary and Management Guide for Clinicians

This section is a fast-reading ADPKD clinician guide focused on current evidence lanes, practical relevance, and visible limitations instead of hand-wavy summaries.

Current evidence lanes

Established human evidence, moderate human evidence, and early signal separated cleanly.

  • Tolvaptan in appropriate high-risk adults (Tier 1)
  • Risk-stratified intervention timing (imaging + eGFR trajectory) (Tier 1)
  • SGLT2 inhibitors in ADPKD (Tier 2 to Tier 3 signal)
  • Metabolic and weight-pathway candidates under active human testing (Tier 3)

Trials and pipeline

Which active programs are worth watching and which ones are still just signal.

  • NCT07282821, Bempedoic Acid Therapy for Polycystic Kidney Disease
  • NCT07454174, Metabolic Impacts of Ren-Nu dietary program for PKD
  • NCT07280585, STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
  • NCT04939935, IMPEDE-PKD: Metformin therapy to ease decline of kidney function in ADPKD

Latest evidence movement

Evidence anchors

Fast reference set for the highest-leverage public-facing claims.

  • PMID23121377, Tolvaptan in patients with autosomal dominant polycystic kidney disease (TEMPO 3:4)
  • PMID29105594, Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease (REPRISE)
  • PMID39848746, KDIGO 2025 ADPKD guideline executive summary
  • PMID36191725, Clinical Pattern of Tolvaptan-Associated Liver Injury in Pivotal Trials
  • NATCOMM2022, PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression
  • PMID41758739, Tolvaptan for ADPKD: real-world propensity score weighted retrospective cohort

Unresolved contradictions worth watching

  • Hydration strategy granularity
  • Emerging non-tolvaptan pharmacologic options
  • Commercial termination vs biological plausibility (e.g., lixivaptan program)
  • Statin hypothesis vs adult RCT outcomes
  • Prognostic biomarker strength vs therapeutic actionability
  • Tolvaptan tolerability optimization vs net renal efficacy certainty (HYDRO-PROTECT)